BR112022006085A2 - COMPOSITIONS THAT PREFERENTIALLY ENHANCE GABAA RECEPTOR SUBTYPES AND METHODS OF THEIR USE - Google Patents

COMPOSITIONS THAT PREFERENTIALLY ENHANCE GABAA RECEPTOR SUBTYPES AND METHODS OF THEIR USE

Info

Publication number
BR112022006085A2
BR112022006085A2 BR112022006085A BR112022006085A BR112022006085A2 BR 112022006085 A2 BR112022006085 A2 BR 112022006085A2 BR 112022006085 A BR112022006085 A BR 112022006085A BR 112022006085 A BR112022006085 A BR 112022006085A BR 112022006085 A2 BR112022006085 A2 BR 112022006085A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
gabaa
receptor subtypes
gabaa receptor
Prior art date
Application number
BR112022006085A
Other languages
Portuguese (pt)
Inventor
D Levin Andrew
Buckley Neil
Original Assignee
Eliem Therapeutics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eliem Therapeutics Uk Ltd filed Critical Eliem Therapeutics Uk Ltd
Publication of BR112022006085A2 publication Critical patent/BR112022006085A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSIÇÕES QUE POTENCIALIZAM PREFERENCIALMENTE SUBTIPOS DE RECEPTORES DE GABAA E MÉTODOS DE USO DAS MESMAS. A invenção fornece composições contendo formas isomericamente puras de neuroesteróides que permitem a modulação preferencial de diferentes subtipos de receptores GABAA, tais como modulação preferencial de receptores a4ß3d GABAA sobre os receptores a1ß2?2 GABAA. A invenção também fornece métodos de tratamento de distúrbios GABAA usando tais composições.COMPOSITIONS THAT PREFERENTIALLY ENHANCE GABAA RECEPTOR SUBTYPES AND METHODS OF THEIR USE. The invention provides compositions containing isomerically pure forms of neurosteroids that allow preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of a4ß3d GABAA receptors over a1ß2?2 GABAA receptors. The invention also provides methods of treating GABAA disorders using such compositions.

BR112022006085A 2019-09-30 2020-09-23 COMPOSITIONS THAT PREFERENTIALLY ENHANCE GABAA RECEPTOR SUBTYPES AND METHODS OF THEIR USE BR112022006085A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962907763P 2019-09-30 2019-09-30
PCT/US2020/052167 WO2021067089A1 (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022006085A2 true BR112022006085A2 (en) 2023-03-14

Family

ID=75338529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006085A BR112022006085A2 (en) 2019-09-30 2020-09-23 COMPOSITIONS THAT PREFERENTIALLY ENHANCE GABAA RECEPTOR SUBTYPES AND METHODS OF THEIR USE

Country Status (9)

Country Link
EP (1) EP4135710A4 (en)
JP (1) JP2022552788A (en)
KR (1) KR20220103707A (en)
CN (1) CN115087450A (en)
BR (1) BR112022006085A2 (en)
CA (1) CA3159087A1 (en)
IL (1) IL291835A (en)
MX (1) MX2022003823A (en)
WO (1) WO2021067089A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4161530A4 (en) * 2020-06-08 2024-06-26 Eliem Therapeutics (UK) Ltd Methods of treating female health conditions related to sex hormones
WO2024020953A1 (en) * 2022-07-28 2024-02-01 湖南科益新生物医药有限公司 Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
PT3498725T (en) * 2013-04-17 2021-09-09 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
WO2016061527A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN109890392A (en) * 2016-10-14 2019-06-14 马瑞纳斯制药公司 Method of the application neurosteroid to realize electroencephalogram (EEG) outburst inhibition
WO2020210116A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof

Also Published As

Publication number Publication date
CA3159087A1 (en) 2021-04-08
EP4135710A4 (en) 2023-12-06
IL291835A (en) 2022-06-01
EP4135710A1 (en) 2023-02-22
WO2021067089A1 (en) 2021-04-08
CN115087450A (en) 2022-09-20
JP2022552788A (en) 2022-12-20
KR20220103707A (en) 2022-07-22
MX2022003823A (en) 2022-08-17

Similar Documents

Publication Publication Date Title
CL2022001271A1 (en) glp-1 receptor agonist and use of it
CO2022002759A2 (en) hpk1 antagonists and their uses
CO2021007068A2 (en) Iraq degraders and uses thereof
CL2021003190A1 (en) Tead inhibitors and uses thereof
CL2018001845A1 (en) 5'-nucleotidase modulators, ecto and their use
CO2021001893A2 (en) Anti-gdf15 antibodies, compositions and methods of use
DOP2022000182A (en) ANTI-EGFR ANTIBODY-DRUG CONJUGATES
DOP2017000298A (en) NRF2 REGULATORS
ECSP22055515A (en) COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR
CO2022008406A2 (en) Iraq degraders and uses thereof
GT201600233A (en) COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE 7 RECEIVER
UY37274A (en) USEFUL REPLACED CARBONUCLEOSIDE DERIVATIVES AS ANTHINEOPLASTIC AGENTS
CO2021013339A2 (en) Stat degraders and their uses
BR112022006085A2 (en) COMPOSITIONS THAT PREFERENTIALLY ENHANCE GABAA RECEPTOR SUBTYPES AND METHODS OF THEIR USE
UY37589A (en) MODULATING COMPOUNDS OF ARYLIC HYDROCARBON RECEIVER (AhR)
UY37590A (en) MODULATING COMPOUNDS OF ARYLIC HYDROCARBON RECEIVER (AhR)
CL2018002810A1 (en) Anti-complement factor bb antibodies and uses of these cross-reference.
CO2020015747A2 (en) Rapamycin analogs and uses thereof
CL2021002357A1 (en) Fused and Related Bicyclic Piperidinyl Compounds as Modulators of the c5a Receptor
DK3721227T3 (en) OLFACTORY RECEPTOR INVOLVED IN THE PERCEPTION OF MUSK FRAGRANCE AND ITS USE
ECSP21088669A (en) NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE
DOP2018000238A (en) ZESTE HOMOLOGIST ENHANCER INHIBITORS 2
CL2019001991A1 (en) Estrogen receptor modulators.
CL2021001027A1 (en) Selective rgmc inhibitors and their use
CO7240378A2 (en) Indolecarbonitriles as selective modulators of androgen receptors